4D Molecular Therapeutics is a pre-clinical stage gene therapy company developing next-generation AAV vectors. The company's proprietary Therapeutic Vector Evolution platform harnesses the power of natural selection to create customized AAV vectors that are designed to provide tissue targeted gene delivery, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies. 4DMT's initial products target patients suffering from Fabry disease, X-linked Retinitis Pigmentosa, and Choroideremia.
Headquarters: Emeryville, CA
Website: https://www.4dmoleculartherapeutics.com/

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) is a clinical stage biotechnology company focused on developing small molecules for the treatment of disorders that are characterized by hypersensitization. The company’s lead drug candidate BLU-5937 for chronic cough is a potent and highly selective oral inhibitor of the P2X3 receptor.
Headquarters: Quebec, Canada
Website: https://bellushealth.com/

Cara Therapeutics, Inc. (Nasdaq: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara’s pipeline of drugs is led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist for treatment of pruritus in patients with chronic kidney disease.
Headquarters: Stamford, Connecticut
Website: https://www.caratherapeutics.com/

Contego Medical is a medical device company dedicated to the development of novel medical devices for neurovascular, cardiovascular and peripheral vascular procedures. The company’s Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
Headquarters: Raleigh, North Carolina
Website: https://contegomedical.com

Eidos Therapeutics, Inc. (NASDAQ: EIDX) is developing a novel drug to treat all forms of Transthyretin (TTR) amyloidosis, a condition characterized by toxic amyloid aggregates in the heart and peripheral nerves. The lead candidate, AG10 is an orally-administered, small molecule designed to mimic a naturally-occurring genetic rescue mutation that protects high-risk individuals from developing TTR amyloidosis.
Headquarters: San Francisco, California
Website: http://eidostx.com/

Essential Medical es una compañía de tecnología médica que desarrolla dispositivos de cierre vascular para punciones femorales posteriores a los procedimientos de cateterismo cardíaco. Estos procedimientos cardíaco, como TAVR y EVAR, son algunos de los segmentos que destacan la necesidad para proporcionar soluciones rápida, fácil y sin complicaciones para el cierre vascular.
Headquarters: Malvern, Pennsylvania
Website: http://www.essmedclosure.com/

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM TM, which is delivered by the company’s Optimizer® Smart System. CCM is first-of-a-kind, FDA approved, life-changing treatment for a large population of heart failure patients with limited treatment options.
Headquarters: Mount Laurel, New Jersey
Website: https://impulse-dynamics.com/

Inspire Medical Systems, Inc. (NYSE: INSP) developed the world's first fully implantable neurostimulation system for treatment of obstructive sleep apnea. The device works by opening up the upper airway in synchrony with patient's breathing during sleep through gentle stimulation of the key airway muscles. It offers a safe, effective and minimally invasive alternative to millions of patients who have failed or are intolerant of Continuous Positive Airway Pressure (CPAP).
Headquarters: Maple Grove, Minnesota
Website: https://www.inspiresleep.com/

Iterum Therapeutics plc (NASDAQ:ITRM) is dedicated to developing differentiated anti-infectives aimed at combatting multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations for the treatment of uncomplicated and complicated urinary tract infection and complicated intra-abdominal infection.
Headquarters: Dublin, Ireland
Website: http://www.iterumtx.com

MEI Pharma, Inc. (NASDAQ: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company’s diverse portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Headquarters: San Diego, California
Website: http://www.meipharma.com

MIACH Orthopaedics, Inc. is a medical technology company developing innovative bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable high performance alternative to conventional ACL reconstruction using grafts. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery.
Headquarters: Boston, Massachusetts

Monte Rosa Therapeutics is a pre-clinical stage biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a proprietary platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. Monte Rosa hopes to deliver pioneering therapies for cancer and beyond.
Headquarters: Boston, MA
Website: https://www.monterosatx.com/

Oyster Point Pharma, Inc. (Nasdaq: OYST) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization novel therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 works by restoring natural tear film production.
Headquarters: Princeton, New Jersey
Website: https://oysterpointrx.com/

Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta is combining its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. SEL-212, the company’s lead candidate is being developed to treat severe gout patients.
Headquarters: Watertown, Massachusetts
Website: http://selectabio.com/

ShiraTronics, Inc. is an emerging medical device company developing an innovative neuromodulation approach to treat refractory migraine headaches.
Headquarters: Brooklyn Park, Minnesota
Website: https://shiratronics.com/